FDA's Approval For Sarepta's Duchenne Gene Therapy, A Boost for Taysha Gene's Rare Neuropathy Treatment: Analyst Weighs

On Friday, the FDA's adcomm voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's SRPT SRP-9001 (delandistrogene moxeparvovec) for ambulatory patients with Duchenne muscular dystrophy.

Truist analyst writes that given the controversial dataset with an equally controversial mechanism of action of SRPT-9001, the vote comes as a surprise. However, despite being narrow, it is positive for Taysha Gene Therapies Inc's TSHA TSHA-120. 

The analyst has raised the price target to $3 from $2 with a Buy rating.

It says that the FDA would eventually recognize that a placebo-controlled study of TSHA-120 for giant axonal neuropathy (GAN) is not feasible due to the ultra-rare nature of the disease and accept natural history as a reasonable comparator. 

The replacement of the full copy of the GAN gene, gigaxonin, used in TSHA-120 has a stronger rationale than the controversial micro-dystrophin for DMD. 

The analyst also notes that TSHA-120's safety and efficacy data is impressive compared to the limited dataset available for SRPT-9001.

The formal FDA meeting request submission to discuss the regulatory path forward for TSHA-120 in GAN is expected in Q2 2023; the formal meeting is anticipated in Q3 2023.

Price Action: TSHA shares are up 3.44% at $0.69 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsPenny StocksHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!